aTyr Pharma stock: EUR 0.16 puts aTyr Pharma stock 196.30 percent above Frankfurt close
Published on 10/22/2026 at 19:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and price move
- TradingView reported an average target of USD 3.20 from USD 2.83 on October 22, 2026.
- aTyr Pharma recorded a USD 10.31 million loss in the second quarter of fiscal 2026.
- aTyr Pharma stock costs EUR 0.16 at Lang & Schwarz on October 22, 2026 at 7:42 p.m. CEST, 196.30 percent above the Frankfurt close of October 21, 2026.
- The Nasdaq-listed company had a USD 17.3 million market capitalization as of October 20, 2026.
aTyr Pharma stock (ISIN US0021202025) stood at EUR 0.16 at Lang & Schwarz on October 22, 2026 at 7:42 p.m. CEST, 196.30 percent above the Frankfurt close of October 21, 2026 at EUR 0.05. The sharp euro move comes as TradingView reported on October 22, 2026 that five analysts had lifted the average 12-month target from USD 2.83 to USD 3.20.
Analyst target resets the frame
The target change gives the company a fresh valuation reference, but the range remains wide. TradingView reported forecasts from USD 1.00 to USD 7.00 per share and a Buy consensus from seven analysts, including three Buy ratings and four Holds.
The target discussion also contrasts with the companys operating profile. Yahoo Finance lists a USD 10.31 million loss for the second quarter of fiscal 2026, while trailing revenue stood at USD 190,000.
Nasdaq range remains wide
On the Nasdaq, the stock was trading at USD 0.17 on October 22, 2026 at 1:48 p.m. EDT. Yahoo Finance lists a 52-week range of USD 0.17 to USD 1.11, volume of 550,419 shares and a market capitalization of USD 17.3 million as of October 20, 2026. The same page reports a year-to-date decline of 77.42 percent.
Valuation and upcoming date
The Nasdaq listing and company identity are confirmed on the aTyr Pharma investor page, which describes efzofitimod as the lead candidate in development for pulmonary sarcoidosis and lists ATYR on Nasdaq. Yahoo Finance gives November 5, 2026 as the estimated earnings date.
Comparison with peers
aTyr Pharma: up 196.30 percent, negative P/E of -0.28, market capitalization USD 17.0 million. Vertex Pharmaceuticals (Nasdaq, USD): up 1.98 percent, P/E 31.17, market capitalization USD 135.6 billion. Ionis Pharmaceuticals (Nasdaq, USD): down 0.93 percent, P/E -12.66, market capitalization USD 7.3 billion.
What the figures mean for the stock
The contrast is stark: a USD 3.20 average target sits beside a USD 10.31 million quarterly loss and a USD 190,000 trailing revenue figure. For investors, the central question is whether efzofitimod can turn the development pipeline into commercial revenue.
Stock price after hours
The euro quotation is 196.30 percent above the Frankfurt close of October 21, 2026, placing the Lang & Schwarz indication well above the previous German-market level. The primary Nasdaq quote was still USD 0.17 during the US session on October 22, 2026.
The further course of trading is shown by the continuously updated real-time quote of aTyr Pharma stock.
aTyr Pharma market facts
- Company: aTyr Pharma, Inc.
- ISIN: US0021202025
- Ticker: ATYR
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 22, 2026, 7:42 p.m. CEST): EUR 0.16
- Change versus Frankfurt close: plus 196.30 percent
- Frankfurt close (October 21, 2026): EUR 0.05
- Market capitalization: USD 17.3 million (as of October 20, 2026)
- 52-week range: USD 0.17-1.11 (as of October 22, 2026)
- Sector / Industry: Healthcare / Biotechnology
Market context: Market report S&P 500.
